SOLID BIOSCIENCES INC (SLDB) Stock Fundamental Analysis
NASDAQ:SLDB - Nasdaq - US83422E2046 - Common Stock - Currency: USD
We assign a fundamental rating of 2 out of 10 to SLDB. SLDB was compared to 572 industry peers in the Biotechnology industry. While SLDB seems to be doing ok healthwise, there are quite some concerns on its profitability. SLDB is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year SLDB has reported negative net income.
In the past year SLDB has reported a negative cash flow from operations.
In the past 5 years SLDB always reported negative net income.
In the past 5 years SLDB always reported negative operating cash flow.
1.2 Ratios
SLDB has a Return On Assets (-39.26%) which is in line with its industry peers.
SLDB has a better Return On Equity (-46.93%) than 67.79% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -39.26% | ||
| ROE | -46.93% | ||
| ROIC | N/A |
ROA(3y)-40.77%
ROA(5y)-57.43%
ROE(3y)-50.4%
ROE(5y)-72.91%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for SLDB so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
SLDB does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SLDB has been increased compared to 1 year ago.
SLDB has more shares outstanding than it did 5 years ago.
SLDB has a worse debt/assets ratio than last year.
2.2 Solvency
SLDB has an Altman-Z score of -2.59. This is a bad value and indicates that SLDB is not financially healthy and even has some risk of bankruptcy.
SLDB's Altman-Z score of -2.59 is in line compared to the rest of the industry. SLDB outperforms 49.91% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that SLDB is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.00, SLDB perfoms like the industry average, outperforming 44.60% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.59 |
ROIC/WACCN/A
WACC9.38%
2.3 Liquidity
A Current Ratio of 13.45 indicates that SLDB has no problem at all paying its short term obligations.
With an excellent Current ratio value of 13.45, SLDB belongs to the best of the industry, outperforming 87.26% of the companies in the same industry.
A Quick Ratio of 13.45 indicates that SLDB has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 13.45, SLDB belongs to the top of the industry, outperforming 87.26% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 13.45 | ||
| Quick Ratio | 13.45 |
3. Growth
3.1 Past
SLDB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 54.08%, which is quite impressive.
Looking at the last year, SLDB shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
EPS 1Y (TTM)54.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%24.76%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
SLDB is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.73% yearly.
Based on estimates for the next years, SLDB will show a very strong growth in Revenue. The Revenue will grow by 156.67% on average per year.
EPS Next Y37.56%
EPS Next 2Y17.21%
EPS Next 3Y11.74%
EPS Next 5Y8.73%
Revenue Next Year-100%
Revenue Next 2Y-46.7%
Revenue Next 3Y-25.99%
Revenue Next 5Y156.67%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for SLDB. In the last year negative earnings were reported.
Also next year SLDB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.21%
EPS Next 3Y11.74%
5. Dividend
5.1 Amount
SLDB does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SOLID BIOSCIENCES INC
NASDAQ:SLDB (2/11/2025, 12:16:02 PM)
3.155
-0.29 (-8.28%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners79.89%
Inst Owner Change-55.18%
Ins Owners0.85%
Ins Owner Change0.32%
Market Cap126.04M
Analysts85.56
Price Target17.24 (446.43%)
Short Float %7.14%
Short Ratio5.16
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.9%
Min EPS beat(2)1.9%
Max EPS beat(2)9.9%
EPS beat(4)4
Avg EPS beat(4)6.48%
Min EPS beat(4)0.77%
Max EPS beat(4)13.35%
EPS beat(8)7
Avg EPS beat(8)0.95%
EPS beat(12)9
Avg EPS beat(12)2.41%
EPS beat(16)12
Avg EPS beat(16)4.27%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.59%
PT rev (3m)-8.65%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0.18%
EPS NY rev (3m)-7.37%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.65 | ||
| P/tB | 0.65 | ||
| EV/EBITDA | N/A |
EPS(TTM)-3.04
EYN/A
EPS(NY)-3.01
Fwd EYN/A
FCF(TTM)-2.16
FCFYN/A
OCF(TTM)-2.14
OCFYN/A
SpS0
BVpS4.84
TBVpS4.84
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -39.26% | ||
| ROE | -46.93% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-40.77%
ROA(5y)-57.43%
ROE(3y)-50.4%
ROE(5y)-72.91%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 38.51% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 13.45 | ||
| Quick Ratio | 13.45 | ||
| Altman-Z | -2.59 |
F-Score6
WACC9.38%
ROIC/WACCN/A
Cap/Depr(3y)75.75%
Cap/Depr(5y)81.18%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)54.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%24.76%
EPS Next Y37.56%
EPS Next 2Y17.21%
EPS Next 3Y11.74%
EPS Next 5Y8.73%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-46.7%
Revenue Next 3Y-25.99%
Revenue Next 5Y156.67%
EBIT growth 1Y8.21%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-16.93%
EBIT Next 3Y-11.03%
EBIT Next 5YN/A
FCF growth 1Y-2.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-3.67%
OCF growth 3YN/A
OCF growth 5YN/A